Reveal is developing RVP-001, a gadolinium-free MRI contrast agent based on manganese, which eliminates the accumulation of heavy metals in patients and reduces environmental contamination. This agent is currently in Phase 2 clinical studies and aims to replace existing contrast agents, enhancing patient safety and protecting aquatic ecosystems.
Funding
$50K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current MRI contrast agents based on gadolinium lead to the accumulation of heavy metals in patients' bodies and contribute to environmental contamination, posing risks to both human health and aquatic ecosystems.
Solution
Reveal is developing RVP-001, a gadolinium-free MRI contrast agent utilizing manganese, an essential trace element. RVP-001 is designed as a direct replacement for existing contrast agents, aiming to enhance patient safety by eliminating gadolinium accumulation and reduce environmental impact. The agent is currently undergoing Phase 2 clinical studies. Reveal is also developing fibrogenesis imaging agents designed to identify active fibrotic disease, with potential applications in diagnosis, staging, patient stratification, and monitoring treatment response across various fibrotic diseases.
Target Audience
The primary target audience includes radiologists, hospitals, and imaging centers seeking safer and more environmentally friendly MRI contrast agents.
Features
- Gadolinium-free formulation based on manganese, minimizing heavy metal accumulation in patients.
- Designed as a direct replacement for current gadolinium-based MRI contrast agents.
- Actively advancing through Phase 2 clinical studies.
- Pipeline includes fibrogenesis imaging agents for diagnosis and monitoring of fibrotic diseases.